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Whereas regular allocation avoids unacceptable mismatches on the donor organ, al-
location to highly sensitized patients within the Eurotransplant Acceptable Mismatch 
(AM) program is based on the patient's HLA phenotype plus acceptable antigens. 
These are HLA antigens to which the patient never made antibodies, as determined 
by extensive laboratory testing. AM patients have superior long-term graft survival 
compared with highly sensitized patients in regular allocation. Here, we questioned 
whether the AM program also results in lower rejection rates. From the PROCARE 
cohort, consisting of all Dutch kidney transplants in 1995-2005, we selected de-
ceased donor single transplants with a minimum of 1 HLA mismatch and determined 
the cumulative 6-month rejection incidence for patients in AM or regular allocation. 
Additionally, we determined the effect of minimal matching criteria of 1 HLA-B plus 
1 HLA-DR, or 2 HLA-DR antigens on rejection incidence. AM patients showed sig-
nificantly lower rejection rates than highly immunized patients in regular allocation, 
comparable to nonsensitized patients, independent of other risk factors for rejection. 
In contrast to highly sensitized patients in regular allocation, minimal matching criteria 
did not affect rejection rates in AM patients. Allocation based on acceptable antigens 
leads to relatively low-risk transplants for highly sensitized patients with rejection 
rates similar to those of nonimmunized individuals.
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1  | INTRODUC TION
Sensitization toward HLAs can occur through pregnancy, blood trans-
fusion, or transplant.1 When a patient has formed antibodies reactive 
>85% of HLA antigens present in the donor population, this patient is 
regarded as being highly sensitized.2 Highly sensitized patients accrue 
on the transplant waitlist due to the low number of available cross-
match-negative donors. The Eurotransplant Acceptable Mismatch 
program was established almost 30 years ago with the aim to provide 
a chance for highly sensitized patients to be transplanted, which has 
resulted in >1500 transplants.3 The program is based on the positive 
identification of HLA antigens to which the patient has not made any 
antibodies by using extensive laboratory testing.4 Acceptable an-
tigens are added to the HLA phenotype of the patient, creating an 
“extended” HLA phenotype, which is used for allocation.5 Any avail-
able deceased donor organ that matches this extended phenotype 
is mandatorily allotted to the AM patient, resulting in lower waiting 
times for these highly sensitized patients.6,7 Acceptable antigens are 
truly acceptable, because no HLA match effect is observed in patients 
transplanted through the AM program.5,7 Previously, it was shown 
that the long-term graft survival of patients transplanted through the 
AM program is far superior to that of their highly sensitized counter-
parts transplanted through regular allocation and was even compa-
rable to that of nonsensitized patients.7,8 Because the AM strategy is 
targeted at defining HLA antigens that are immunologically accept-
able, it is to be expected that allocation based on acceptable antigens 
would also result in a lower rejection incidence. Unfortunately, due to 
a lack of registration of rejection data in the Eurotransplant Network 
Information System, it has not been possible so far to determine the 
effect of the AM approach on rejection rates. The Dutch multicenter 
PROCARE study, which includes clinical follow-up of all kidney trans-
plants performed between 1995 and 2005 in the Netherlands, al-
lowed for the first time the determination of the effect of allocation 
on rejection rates based on acceptable mismatches.
2  | METHODS
2.1 | The AM program
Current eligibility criteria for inclusion into the AM program are a cu-
mulative waiting time on the Eurotransplant Kidney Allocation System 
(ETKAS) waitlist of ≥ 2 years and a CDC PRA of >85% in either historic 
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or current serum samples. In the period of 1995-2005, acceptable anti-
gens were defined by making use of mainly cellular assays, as described 
elsewhere.5 Briefly, CDC assays were performed by using patient-spe-
cific cell panels of lymphocytes that had only 1 HLA mismatch with the 
patient, in which negative reactions would specify acceptable antigens. 
Similarly, a panel of K562 cell lines transfected with genes encoding 
single HLA class I alleles were used as targets in CDC. In the time pe-
riod studied, solid phase assays were not routinely used.
For allocation purposes, HLA matching on the patient's own 
HLA antigens and additional acceptable antigens was performed 
on the split antigen level. Minimal match criteria on the identity of 
either 2 HLA-DR antigens or 1 HLA-DR antigen with 1 HLA-B an-
tigen at the split level were adhered to. For patients with a chance 
of receiving a kidney through the AM program of <0.1% (based 
on immunological grounds), minimal HLA matching was reduced 
to 1 HLA-DR match with the patient on the broad antigen level. 
Furthermore, whereas regular allocation through ETKAS is based 
on blood group identity, AM patients are transplanted based on 
blood group compatibility.
2.2 | Patients
We performed a post hoc analysis on the PROCARE cohort, which 
includes all renal transplants performed in the Netherlands be-
tween January 1995 and December 2005 with available clinical 
follow-up.9 All transplants required a negative CDC crossmatch 
using both peak and current sera. A detailed description of the co-
hort has been published previously.10 Clinical data were obtained 
from the Dutch Organ Transplant Registry. Rejection was defined 
as the presence of biopsy-proved acute rejection (without further 
classification) or any treatment for acute rejection when no biopsy 
was performed. Patients transplanted through regular allocation 
(ETKAS) were grouped according to the level of sensitization (0% to 
5% peak PRA: nonsensitized; 6% to 85% peak PRA: intermediately 
sensitized; and >85% peak PRA: highly sensitized), as defined by 
CDC assays. Patients included on the AM waitlist remained on the 
ETKAS waitlist as well, and those who were actually transplanted 
through ETKAS (and thus received an organ based on the absence 
of unacceptable antigens only) are included in the >85% PRA ETKAS 
TA B L E  1   Patient characteristics
Parameters Categories
ETKAS
AM Total
P
0‐5% PRA 6‐85% PRA >85% PRA
N = 1991 N = 968 N = 121 N = 113 N = 3193
Sex of recipient Female 34.3% 48.5% 59.5% 68.1% 1301 <.001
Male 65.7% 51.5% 40.5% 31.9% 1892
Sex of donor Female 48.8% 44.6% 47.9% 43.4% 1510 .156
Male 51.2% 55.4% 52.1% 56.6% 1683
Age of recipient (y) ≤50 46.3% 53.9% 64.5% 64.6% 1594 <.001
>50 53.7% 46.1% 35.5% 35.4% 1599
Age of donor (y) ≤50 57.3% 63.1% 61.2% 58.4% 1891 .023
>50 42.7% 36.9% 38.8% 41.6% 1302
Donor type HB 66.5% 73.9% 90.1% 99.1% 2260 <.001
NHB 33.5% 26.1% 9.9% 0.9% 933
Repeat transplant No 93.4% 71.6% 40.5% 46.0% 2654 <.001
Yes 6.6% 28.4% 59.5% 54.0% 539
HLA-A, -B, -DR 
mismatch (broad 
antigen level)
1, 2, 3 82.5% 81.7% 84.3% 90.3% 2637 .144
4, 5, 6 17.5% 18.3% 15.7% 9.7% 556
Transplant period 1996-2000 45.0% 57.5% 63.6% 42.5% 1577 <.001
2001-2005 55.0% 42.5% 36.4% 57.5% 1616
Initial immunosup-
pressiona 
Pred/cyclo ± MMF 
± IL2RA
65.8% 63.2% 64.7% 42.6% 1497 .002
Pred/tacro/MMF ± 
IL2RA
34.2% 36.8% 35.3% 57.4% 828
Initial graft functionb  Direct 64.5% 69.3% 67.3% 79.6% 1991 .002
Delayed 35.5% 30.7% 32.7% 20.4% 997
 AM, acceptable mismatch; cyclo, cyclosporine; HB, heart beating; IL2RA, interleukin-2 receptor antagonist; MMF, mycophenolate mofetil; NHB, 
non–heart beating; pred, prednisolone; tacro, tacrolimus.
aMissing values (n = 868), bmissing values (n = 209). P-values calculated with χ2 test.
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group. The study design is schematically depicted in Figure S1, and 
patient characteristics are depicted in Table 1. All patients provided 
written informed consent for use of their clinical data. The study 
protocol was approved by the Biobank Research Ethics Committee 
of the UMC Utrecht (TC Bio 13-633) and performed in accordance 
with the Declaration of Helsinki.
2.3 | Detection and definition of DSAs by 
solid phase
All available pretransplant patient sera were retrospectively tested 
for the presence of donor-specific antibodies (DSAs) by Luminex sin-
gle antigen bead assays and analyzed in context of the PROCARE 
study as described previously.10
2.4 | Data handling
Groupings of quantitative variables were based on the following 
strategies: transplant period was divided into 2 equal periods, and 
recipient and donor ages of 50 years were used for stratification 
based on previous studies.11 Donor type was defined as either heart 
beating (HB) or non–heart beating (NHB). Initial immunosuppression 
was categorized as prednisolone/cyclosporine with or without my-
cophenolate mofetil (MMF) with or without interleukin (IL)-2 recep-
tor antagonist (IL2RA) versus prednisolone/tacrolimus/MMF with or 
without IL2RA based on a previous study on the complete PROCARE 
cohort.12 Graft function was categorized on direct or delayed func-
tion, and HLA mismatches were divided into equal categories.
2.5 | Statistical analysis
The χ2 test was used to test whether there was a trend in the propor-
tions with transplant characteristics over the 4 categories. Statistical 
significance was determined by using the log-rank test, corrected 
for multiple comparisons (Bonferroni method), where applicable. 
Inclusion criterion for the multivariate analysis was a univariate P-
value of <.1. Multivariate Cox regression analysis was performed to 
determine independent effects on 6-month cumulative rejection 
incidence. P-values were 2-tailed, and those <.05 were considered 
statistically significant. SPSS version 23 (IBM, Armonk, NY) and 
GraphPad Prism, version 7.04 (GraphPad Software, La Jolla, CA) 
were used.
3  | RESULTS
3.1 | Allocation based on acceptable mismatches 
results in low rejection rates
To determine the effect of allocation based on acceptable mismatches 
on the 6-month cumulative rejection incidence, we selected all de-
ceased donor single renal transplants from 1996 to 2005 (in 1996, 
ETKAS was initiated13) with ≥ 1 HLA antigen mismatch (HLA-A, -B, 
or -DR) at the broad antigen level. We observed an increased rejec-
tion incidence with increased sensitization grade within regular allo-
cation, with the highest incidence of rejection in the highly sensitized 
patients transplanted through ETKAS (Figure 1A). In contrast, highly 
sensitized patients transplanted through the AM program showed 
F I G U R E  1   A, Comparison of 6-month cumulative rejection incidence between patients transplanted through the acceptable mismatch 
(AM) program or through the Eurotransplant Kidney Allocation System (ETKAS). B, Comparison of 5-year cumulative rejection incidence 
between patients transplanted through the AM program or through ETKAS, for which rejection incidence was set at zero on 6 months. The 
ETKAS patients are subdivided based on their sensitization grade: 0% to 5% peak PRA: nonsensitized; 6% to 85% peak PRA: intermediately 
sensitized; and >85% peak PRA: highly sensitized. P value calculated with log-rank test and corrected for multiple comparisons (Bonferroni 
method)
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TA B L E  2   Factors affecting 6-month cumulative rejection incidence of highly sensitized transplant recipients (>85% PRA) within 
PROCARE cohort (>0 HLA-A, -B, -DR mismatch)
 
Cox regression
Univariate Multivariate Multivariate
HR 95% CI P HR 95% CI P HR 95% CI P
Sex of recipient
Female (ref)             
Male 0.797 0.489 1.300 .364         
Sex of donor
Female (ref)             
Male 0.949 0.599 1.504 .824         
Age of recipient (y)
≤50 (ref)             
>50 0.819 0.502 1.334 .422         
Age of donor (y)
≤50 (ref)             
>50 1.240 0.781 1.969 .362         
Donor type
HB (ref)             
NHB 1.176 0.429 4.224 .752         
Repeat transplant
No (ref)             
Yes 0.786 0.497 1.245 .305         
HLA-A, -B, -DR mismatch (broad antigen level)
1, 2, 3 (ref)             
4, 5, 6 1.353 0.712 2.570 .356         
Luminex defined DSA
No (ref)             
HLA class I 1.292 0.734 2.276 .374         
HLA class II 0.691 0.240 1.991 .493         
HLA class I and class II 1.420 0.612 3.296 .415         
Transplant period
1996-2000 (ref)             
2001-2005 0.632 0.394 1.012 .056     0.642 0.387 1.064 .086
Initial immunosuppression
Pred/cyclo ± MMF ± IL2RA 
(ref)
            
Pred/tacro/MMF ± IL2RA 0.581 0.306 1.104 .097 0.665 0.345 1.282 .223     
Initial graft function
Direct (ref)             
Delayed 1.941 1.190 3.167 .008     1.925 1.163 3.187 .011
Tx through AM program
No (ref)             
Yes 0.469 0.290 0.758 .002 0.541 0.272 1.073 .079 0.569 0.342 0.945 .029
 AM, acceptable mismatch; CI, confidence interval; cyclo, cyclosporine; DSA, donor-specific antibody; HB, heart beating; HR, hazard ratio; IL2RA, 
interleukin-2 receptor antagonist; MMF, mycophenolate mofetil; NHB, non–heart beating; pred, prednisolone; ref, reference value; tacro, tacrolimus; 
Tx, transplant.
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similar rejection rates to those of nonsensitized patients (P = 1.000) 
and lower, although not significant, rejection rates than intermedi-
ately sensitized patients (P = .423). When compared with their highly 
sensitized counterparts transplanted through regular allocation, 
AM patients experienced a significantly lower rejection incidence 
(P = .004, Figure 1A). To determine the effect of the different al-
location schemes on rejection rates later after transplant, we also 
analyzed the cumulative rejection incidence between 6 months and 
5 years and observed no differences in this later period (Figure 1B).
We next performed univariate Cox regression analysis on all 
highly sensitized patients (n = 234) with variables that potentially 
affect the rejection incidence (Table 2). The variables of sex and age 
of the recipient and the donor, donor type, first transplant versus 
repeat transplant, HLA mismatch grade, transplant period, initial 
immunosuppression, and presence of single antigen bead–detected 
DSAs of class I, class II, or both class I and class II did not signifi-
cantly affect the cumulative 6-month rejection incidence. The only 
variables that affected the incidence of rejection were delayed graft 
function (hazard ratio [HR] 1.94, 95% confidence interval [CI] 1.19 
to 3.17; P = .008) and receiving a transplant through the AM pro-
gram (HR 0.47, 95% CI 0.29 to 0.76; P = .002). The variables of trans-
plant period, initial immunosuppression, initial graft function, and 
transplant through the AM program were selected for subsequent 
multivariate analysis to determine whether the effect of receiving 
a transplant through the AM program was independent. For initial 
immunosuppression, there were missing values for 88 patients (38%) 
due to heterogeneous immunosuppression protocols outside the 2 
main immunosuppression categories. To exclude an interaction be-
tween initial immunosuppression and transplant through the AM 
program, we first analyzed these variables in a separate multivariate 
analysis and observed only a minimal effect of initial immunosup-
pression on the variable transplant through the AM program (HR 
changes from 0.47 to 0.54, Table 2). Subsequent multivariate anal-
yses on transplant period, initial immunosuppression, initial graft 
function, and transplant through the AM program showed that only 
delayed graft function (HR 1.93, 95% CI 1.16 to 3.19; P = .011) and 
receiving a transplant through the AM program (HR 0.57, 95% CI 
0.34 to 0.95; P = .029) were independently associated with 6-month 
cumulative rejection incidence (Table 2).
3.2 | Minimal match criteria do not result in lower 
rejection rates in AM patients
It has previously been shown that AM patients transplanted with 
a minimal match level of 2 HLA-DR antigens or of 1 HLA-DR and 
1 HLA-B antigen have similar graft survival rates compared with 
AM patients without this minimal level of HLA matching, raising the 
possibility that the minimal match criteria for AM patients could be 
abandoned.3 Importantly, in the current cohort we were able to de-
termine the effect of the minimal match criteria on rejection rates. 
For this analysis, we also included patients with 0 HLA mismatches 
(Figure S1). We found that receiving a transplant without the afore-
mentioned minimal match level, but a minimum match of 1 HLA-
DR on the broad antigen level, significantly increased the 6-month 
F I G U R E  2   Minimal match criteria do not affect rejection rates for patients transplanted through the Acceptable Mismatch (AM) program. 
A, The 6-month cumulative rejection incidence of highly sensitized patients transplanted through the Eurotransplant Kidney Allocation 
System (ETKAS) with a minimal match level of 1 HLA-B and 1 HLA-DR antigen, or 2 HLA-DR antigens on the split antigen level (equivalent 
to minimal match criteria), or transplanted with 1 HLA-DR match at the broad antigen level. B, The 6-month cumulative rejection incidence 
of AM patients transplanted according to the minimal match criteria of 1 HLA-B and 1 HLA-DR antigen, or 2 HLA-DR antigens on the split 
antigen level, or transplanted 1 HLA-DR match at the broad antigen level
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cumulative rejection incidence in patients transplanted through 
ETKAS (P < .0001, Figure 2A), whereas no effect was found in the 
AM cohort (P = .700, Figure 2B). The data indicate that the minimal 
match criteria are not beneficial over 1 HLA-DR broad antigen match 
for patients transplanted through the AM program.
4  | DISCUSSION
It is known that transplant to sensitized patients through regular al-
location is associated with an elevated risk for graft rejection.14-16 
The current study confirms these data, with the cumulative rejection 
incidence for highly sensitized patients transplanted through ETKAS 
being almost double that of nonsensitized ETKAS patients. In con-
trast, patients transplanted through the AM program showed signifi-
cantly lower rejection rates compared with highly sensitized patients 
transplanted through regular allocation and even had similar rejection 
rates as nonsensitized patients. On multivariate analysis, receiving a 
transplant through the AM program remained independently associ-
ated with low rejection rates in highly sensitized patients. The occur-
rence of rejection is known to be a risk factor for subsequent inferior 
long-term graft survival.17 Indeed, it has been described previously 
that graft survival in AM patients is far superior to that in highly sen-
sitized patients transplanted through ETKAS and comparable to that 
in nonsensitized ETKAS patients.7 Limitations of the study are that 
it does not include information on whether the rejections were bi-
opsy proven. In the PROCARE database, rejection was defined as a 
registered treatment for rejection, of which 56.4% (n = 456) were ac-
companied by a documented biopsy specimen taken a day before or 
at the day of initiation of antirejection treatment, a percentage that 
was evenly distributed between the different groups (P = .122, Table 
S1). This is likely an underestimation due to incompleteness of the da-
tabase for this field. To obtain a more stringent selection on the rejec-
tion events, we determine the 6-month cumulative rejection of highly 
sensitized patients (ETKAS and AM) without any rejection or who 
received a documented biopsy-informed antirejection treatment de-
fined as described earlier and again found that patients transplanted 
through AM had a significantly lower rejection incidence than their 
highly sensitized counterparts transplanted through (Figure S2).
Second, we were unable to further differentiate in type of rejec-
tion, because a classification of rejection is not available from the 
Dutch Organ Transplant Registry and cannot be obtained retrospec-
tively due to the various changes in BANFF criteria over time. Finally, 
there are no data available regarding development of de novo DSAs 
in the current cohort. With the current study showing a marked ben-
efit for AM patients, these parameters should be included in a con-
secutive study on a more recent cohort.
The finding that allocation based on acceptable antigens results in 
low rejection rates and excellent long-term graft survival can be ex-
plained in several ways. First, the absence of particular HLA antibody 
specificities is actively determined for AM patients in both historic and 
current sera, in contrast to regular allocation in which unacceptable an-
tigens are determined and all other antigens are presumed acceptable. 
Second, there is evidence that acquired neonatal tolerance explains a 
proportion of acceptable antigens, because acceptable antigens often 
include the noninherited maternal antigens.18,19 Third, either accept-
able antigens could harbor a low level of epitope mismatches with the 
patient or the epitope mismatches that are present are of low immu-
nogenicity.20 Preliminary data suggest the latter, because analysis for 
HLA class I shows similar levels of epitope mismatches for AM patients 
and patients transplanted through regular allocation, with no effect of 
the number of epitope mismatches on graft survival for AM patients 
(Heidt et al, manuscript in preparation).
Currently, acceptable antigens for HLA-DQA, HLA-DPA, and 
HLA-DPB are not yet accounted for in the AM program, which 
leaves the possibility that rejection rates for AM patients could 
be even lower when these loci are also taken into consideration. 
Indeed, HLA-DQ seems to be the dominant target for HLA anti-
bodies after transplant.21,22 Future analyses should show whether 
extension of acceptable mismatches to these additional loci will in-
deed lead to better outcome. Such analyses should preferentially 
be performed in the whole AM population, because in the current 
study only transplants performed in the Netherlands were included. 
However, the definition of acceptable antigens is done centrally at 
the Eurotransplant Reference Laboratory, using the same criteria for 
all patients within Eurotransplant. While confirmation of our results 
within the whole of Eurotransplant is desirable, we expect similar 
results to the current study.
In addition to a previously described lack of effect of minimal 
match criteria on long-term graft survival in AM patients,3 we show 
a lack of effect on rejection incidence as well, confirming that accept-
able mismatches are truly acceptable. Together, these data strongly 
support downscaling the minimal match criteria for AM patients to 1 
HLA-DR broad antigen match, which can result in around 200 addi-
tional transplants to highly sensitized patients through the AM pro-
gram each year.3
Timely transplant of highly sensitized patients is of the utmost 
importance but should be accompanied by low rejection rates and 
long-term graft survival to have a true impact on the waitlist of 
highly sensitized patients. We show that transplant of highly sen-
sitized patients can be achieved with comparable rejection rates to 
nonsensitized patients, when acceptable mismatches are used in the 
allocation process.
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